What is Nomax?
Established in 1982, Nomax has evolved from a niche manufacturer of effervescent potassium supplements into a comprehensive pharmaceutical partner. The company is recognized for its flagship product, Effer-K, while simultaneously serving as a critical contract development and manufacturing organization (CDMO) for various pharmaceutical entities. By maintaining founder-led operations and investing in a state-of-the-art 70,000-square-foot facility, Nomax has solidified its position as a high-capacity provider capable of handling a broad spectrum of complex pharmaceutical formulations. Their market position is defined by a blend of legacy product reliability and modern, scalable R&D infrastructure.
How much funding has Nomax raised?
Nomax has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in Nomax
PPP
Public-Private Partnership
What's next for Nomax?
The infusion of capital is expected to accelerate Nomax's strategic growth initiatives, particularly regarding the expansion of its manufacturing capabilities and R&D throughput. As the pharmaceutical industry faces increasing pressure for localized, high-quality production, Nomax is well-positioned to leverage its existing facility to capture additional market share. Future developments will likely focus on diversifying their product portfolio and deepening partnerships with global pharmaceutical firms, ensuring that the company remains at the forefront of manufacturing innovation while maintaining the operational excellence that has defined its four-decade history.
See full Nomax company page
